Lab chemical and life sciences company
) posted adjusted earnings (excluding restructuring charges) of
$1.05 per share in the third quarter of 2013, above the year-ago
earnings of 94 cents.
The results beat the Zacks Consensus Estimate of $1.00 per
share. The adjusted earnings were positively impacted by
non-recurring tax benefits of $4 million.
Profit, as reported, rose roughly 6.3% year over year to $119
million (or 98 cents per share) in the quarter from $112 million
(or 92 cents per share) a year ago.
Revenues and Margins
Net sales increased 4% year over year to $664 million in the
reported quarter, beating the Zacks Consensus Estimate of $661
million. Organic sales growth in the quarter was 5%, while
foreign exchange translation had a negative impact of 1%.
Adjusted operating margin for the third quarter was 25.3%
compared with 25% recorded a year ago. Adjusted operating margin
in the reported quarter excludes restructuring charges of $10
million related to the closure of a Life Science Products'
manufacturing site in Europe.
Research Chemicals sales were $341 million, up 3% on an organic
basis. The year over year sales increase was supported by
solid sales gains in EMEA (Europe, Middle East and Africa) and
APAC (Asia Pacific) regions. Organic sales growth through the
dealer network was in the high single-digits. Pharma organic
sales growth was in the mid single-digits continuing a
five-quarter trend of sequential improvement.
Applied business unit's sales amounted to $154 million, up 4%
from the prior-year quarter. The organic sales gain was driven by
mid single-digits growth in Diagnostics and Testing division.
However, Industrial sales growth was in the low-to-mid
The ISO 13485 standard certifications for several facilities
in the regulated diagnostics markets helped in expanding segment
offerings. The company has also entered into a partnership with
Paragon Scientific to expand its portfolio of certified reference
materials in the applied markets.
FERRO CORP (FOE): Free Stock Analysis Report
GLOBE SPECIALTY (GSM): Free Stock Analysis
OM GROUP INC (OMG): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.
Sales from the SAFC Commercial segment were $169 million, up 8%
from the third quarter of 2012 on an organic basis. Sales were
driven by strong double-digit gains in Life Science Products and
Life Science Services segments. Contract manufacturing and
biopharma materials also posted strong double-digit rise.
However, Hitech sales declined in the high single-digits. The
industrial cell culture media business performed well in the
Sigma-Aldrich's cash and cash equivalents stood at $688 million
as of Sep 30, 2013, compared with $589 million as of Sep 30,
2012, up 17%. Long-term debt remained flat year over year at $300
million. Debt to capital ratio was 13% as of Sep 30, 2013,
compared with 22% as of Sep 30, 2012. For the first nine months
of 2013, operating cash flow jumped 28.3% year over year to $486
The company repurchased 0.7 million shares during the third
quarter for $59 million. It expects to continue to buyback shares
to offset dilution associated with stock-based compensation.
Sigma-Aldrich reiterated its overall organic sales growth
guidance for 2013. The company expects low-to-mid single-digit
organic sales gain in 2013. However, Sigma-Aldrich altered its
adjusted earnings per share guidance from the previous range of
$4.05 to $4.15 to a new band of $4.08 to $4.15 for the year. The
lower end of the range has been raised due to favorable tax
benefits achieved in the third quarter of 2013.
Free cash flow expectations for the full year have also been
revised by Sigma-Aldrich, which is now expected to exceed $450
million, a $20 million increase from the prior guidance of $430
million. Capital expenditures is expected to be around $110
million. Operating cash flow has been projected to exceed $560
million. Effective tax rate is expected to be about 27% in 2013.
For the remainder of 2013, Sigma-Aldrich is expected to move
forward to capital deployment for mergers/acquisitions, dividends
and share repurchases to generate long-term shareholder value.
Sigma-Aldrich also envisions its customer-focused business units
and initiatives which were taken last year to drive earnings
growth in 2013.
Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).
Globe Specialty Metals, Inc.
), which belongs to the specialty chemical industry, carry a
Zacks Rank #1 (Strong Buy).
OM Group Inc.
), another company in the specialty chemical space, will announce
its third quarter results before the opening bell on Nov 1.